Cancer Database Query Results

Cerv, Cervical Cancer: Click to Expand ⟱
Cervical Cancer
Scientific Papers found: Click to Expand⟱
5472- AF,    Auranofin induces apoptosis and necrosis in HeLa cells via oxidative stress and glutathione depletion
- in-vitro, Cerv, HeLa
TrxR↓, AntiCan↑, TumCG↓, Apoptosis↑, necrosis↑, cl‑PARP↑, MMP↓, ROS↑, GSH↓, eff↓,
5432- AG,    Astragalus polysaccharides combined with radiochemotherapy for cervical cancer: a systematic review and meta-analysis of randomized controlled studies
- Review, Cerv, NA
ChemoSen↑, eff↑, RadioS↑, CEA↓, Wnt↓, β-catenin/ZEB1↓, γH2AX↑, ER Stress↑, mt-TumAuto↑, QoL↑, Imm↑,
1907- AgNPs,  GoldNP,  Cu,    In vitro antitumour activity of water soluble Cu(I), Ag(I) and Au(I) complexes supported by hydrophilic alkyl phosphine ligands
- in-vitro, Lung, A549 - in-vitro, BC, MCF7 - in-vitro, Melanoma, A375 - in-vitro, Colon, HCT15 - in-vitro, Cerv, HeLa
TrxR↓, eff↓, eff↓, other∅,
4403- AgNPs,    Silver Nanoparticles Decorated UiO-66-NH2 Metal-Organic Framework for Combination Therapy in Cancer Treatment
- in-vitro, GBM, U251 - in-vitro, GBM, U87MG - in-vitro, GBM, GL26 - in-vitro, Cerv, HeLa - in-vitro, CRC, RKO
AntiCan↑, eff↑, EPR↑, selectivity↑, ROS↑, Casp↑, Apoptosis↑, DNAdam↑, tumCV↓, eff↑,
4393- AgNPs,    Nanotoxic Effects of Silver Nanoparticles on Normal HEK-293 Cells in Comparison to Cancerous HeLa Cell Line
- in-vitro, Cerv, HeLa - in-vitro, Nor, HEK293
selectivity↓,
4388- AgNPs,    Differential Cytotoxic Potential of Silver Nanoparticles in Human Ovarian Cancer Cells and Ovarian Cancer Stem Cells
- in-vitro, Cerv, NA
tumCV↓, CSCs↓, selectivity↑, Apoptosis↑, ROS↑, LDH↓, Casp3↑, BAX↑, Bak↑, cMyc↑, MMP↓,
4422- AgNPs,    Bioengineering of Piper longum L. extract mediated silver nanoparticles and their potential biomedical applications
- in-vitro, Cerv, HeLa
AntiCan↑, selectivity↑,
4421- AgNPs,    Effect of Biologically Synthesized Silver Nanoparticles on Human Cancer Cells
- in-vitro, Cerv, NA
selectivity↑, eff↝, other↝,
4439- AgNPs,    Anticancer Potential of Green Synthesized Silver Nanoparticles Using Extract of Nepeta deflersiana against Human Cervical Cancer Cells (HeLA)
- in-vitro, Cerv, HeLa
ROS↑, lipid-P↑, MMP↓, GSH↓, TumCCA↑, Apoptosis↑, Necroptosis↑, TumCD↑, Dose↝,
4372- AgNPs,    Negligible particle-specific toxicity mechanism of silver nanoparticles: the role of Ag+ ion release in the cytosol
- in-vitro, Cerv, HeLa - in-vitro, Lung, A549
TumCD↑,
4554- AgNPs,    Involvement of telomerase activity inhibition and telomere dysfunction in silver nanoparticles anticancer effects
- in-vitro, Cerv, HeLa
Telomerase↓, eff↝,
326- AgNPs,  TSA,    Modulating chromatin structure and DNA accessibility by deacetylase inhibition enhances the anti-cancer activity of silver nanoparticles
- in-vitro, Cerv, HeLa
Apoptosis↑, ChrMod↝, eff↑,
324- AgNPs,  CPT,    Silver Nanoparticles Potentiates Cytotoxicity and Apoptotic Potential of Camptothecin in Human Cervical Cancer Cells
- in-vitro, Cerv, HeLa
ROS↑, Casp3↑, Casp9↑, Casp6↑, GSH↓, SOD↓, GPx↓, MMP↓, P53↑, P21↑, Cyt‑c↑, BID↑, BAX↑, Bcl-2↓, Bcl-xL↓, Akt↓, Raf↓, ERK↓, MAP2K1/MEK1↓, JNK↑, p38↑,
312- AgNPs,  wortm,    Inhibition of autophagy enhances the anticancer activity of silver nanoparticles
- vitro+vivo, Cerv, HeLa
APA↑, p62↓, PIK3CA↑, TumVol↓, TumAuto↑, eff↑,
394- AgNPs,    Anticancer activity of Moringa oleifera mediated silver nanoparticles on human cervical carcinoma cells by apoptosis induction
- in-vitro, Cerv, HeLa
ROS↑,
2836- AgNPs,  Gluc,    Glucose capped silver nanoparticles induce cell cycle arrest in HeLa cells
- in-vitro, Cerv, HeLa
eff↝, TumCCA↑, eff↑, eff↑, ROS↑, GSH↓, SOD↓, lipid-P↑, LDH↑,
5343- Ajoene,    The garlic compound ajoene covalently binds vimentin, disrupts the vimentin network and exerts anti-metastatic activity in cancer cells
- in-vitro, Cerv, HeLa - in-vitro, BC, MDA-MB-231
Vim↑, TumCI↓, TumCMig↓, TumMeta↓, Vim↓, other↝,
3435- aLinA,    Alpha-linolenic acid-mediated epigenetic reprogramming of cervical cancer cell lines
- in-vitro, Cerv, HeLa - in-vitro, Cerv, SiHa - in-vitro, Cerv, C33A
DNMTs↓, HDAC↓, HATs↑, hTERT/TERT↓, CDH1↑, RARβ↑, DNMT1↓, DNMT3A↓, TET2↑, HDAC1↓, HDAC8↓, SIRT1↓, HMTs↑, EZH2↓,
421- Api,    Apigenin inhibits HeLa sphere-forming cells through inactivation of casein kinase 2α
- vitro+vivo, Cerv, HeLa
CK2↓,
2635- Api,  CUR,    Synergistic Effect of Apigenin and Curcumin on Apoptosis, Paraptosis and Autophagy-related Cell Death in HeLa Cells
- in-vitro, Cerv, HeLa
TumCD↑, eff↑, TumAuto↑, ER Stress↑, Paraptosis↑, GRP78/BiP↓, Dose↝,
2578- ART/DHA,  RES,    Synergic effects of artemisinin and resveratrol in cancer cells
- in-vitro, Liver, HepG2 - in-vitro, Cerv, HeLa
Dose↝, TumCMig↓, Apoptosis↑, necrosis↑, ROS↑, eff↑,
5175- Ash,    Withaferin A Induces Proteasome Inhibition, Endoplasmic Reticulum Stress, the Heat Shock Response and Acquisition of Thermotolerance
- in-vitro, Cerv, CCL-102
Inflam↓, AntiTum↑, Proteasome↓, ER Stress↑, HSPs↑, GRP94↑, Akt↑, eff↑, HSP70/HSPA5↑,
2337- BBR,    Berberine Inhibited the Proliferation of Cancer Cells by Suppressing the Activity of Tumor Pyruvate Kinase M2
- in-vitro, CRC, HCT116 - in-vitro, Cerv, HeLa
TumCP↓, PKM2↓,
5592- BetA,    Betulin induces mitochondrial cytochrome c release associated apoptosis in human cancer cells
- in-vitro, Liver, HepG2 - in-vitro, Cerv, HeLa
Casp3↑, Casp9↑, cl‑PARP↑, Apoptosis↑, Cyt‑c↑, MMP↓,
5586- BetA,    Suppression of HIF-1α accumulation by betulinic acid through proteasome activation in hypoxic cervical cancer
- in-vitro, Cerv, HeLa
Hif1a↓, VEGF↓, GLUT1↓, PDK1 / PDPK1↓,
5585- BetA,    Betulinic acid-induced mitochondria-dependent cell death is counterbalanced by an autophagic salvage response
- in-vitro, Cerv, HeLa - in-vitro, lymphoma, U937
mtDam↑, TumAuto↑,
2721- BetA,    Proteomic Investigation into Betulinic Acid-Induced Apoptosis of Human Cervical Cancer HeLa Cells
- in-vitro, Cerv, HeLa
ROS↑, Dose↝, Bcl-2↓, BAX↑, ER Stress↑,
2720- BetA,    Betulinic acid induces apoptosis of HeLa cells via ROS-dependent ER stress and autophagy in vitro and in vivo
- in-vitro, Cerv, HeLa
Keap1↝, ROS↑, Ca+2↑, Beclin-1/ATG6↓, GRP78/BiP↑, LC3II↑, p62↑, ERStress↑, TumAuto↑,
2726- BetA,    Betulinic acid induces DNA damage and apoptosis in SiHa cells
- in-vitro, Cerv, SiHa
tumCV↓, DNAdam↑, MMP↓, ROS↑, TumCCA↑, TOP1↓,
2753- BetA,    Betulinic acid induces apoptosis by regulating PI3K/Akt signaling and mitochondrial pathways in human cervical cancer cells
- in-vitro, Cerv, HeLa
PI3K↓, p‑Akt↓, ROS↑, TumCCA↑, p27/CDKN1B↑, P21↑, mt-Apoptosis↑, BAD↑, Casp9↑, MMP↓, eff↓,
5684- BML,    Bromelain mediates apoptosis in HeLa cells via ROS-independent pathway
- in-vitro, Cerv, HeLa
ROS↑, Apoptosis↑, P53↑, TumCMig↓,
7972- BUL,    Mode of action of bullatacin, a potent antitumor acetogenin: inhibition of NADH oxidase activity of HeLa and HL-60, but not liver, plasma membranes
- vitro+vivo, Cerv, HeLa - vitro+vivo, AML, HL-60
NADH↓, selectivity↑,
7978- BUL,    Synthesis and Cytotoxic Property of Annonaceous Acetogenin Glycoconjugates
- in-vitro, Cerv, HeLa - in-vitro, Lung, A549 - in-vitro, Liver, HepG2
*toxicity↑, *BioAv↑,
7969- BUL,    Bullatacin triggered ABCB1-overexpressing cell apoptosis via the mitochondrial-dependent pathway
- NA, Cerv, KBv200
ROS↑, MMP↓, cl‑Casp3↑, cl‑Casp9↓, cl‑PARP↑, Cyt‑c↑, eff↓,
1207- CA,  PacT,    Caffeine inhibits the anticancer activity of paclitaxel via down-regulation of α-tubulin acetylation
- in-vitro, Lung, A549 - in-vitro, Cerv, HeLa
TumCG↑, TumCMig↓, Apoptosis↓, ac‑α-tubulin↑,
1640- CA,  MET,    Caffeic Acid Targets AMPK Signaling and Regulates Tricarboxylic Acid Cycle Anaplerosis while Metformin Downregulates HIF-1α-Induced Glycolytic Enzymes in Human Cervical Squamous Cell Carcinoma Lines
- in-vitro, Cerv, SiHa
GLS↓, NADPH↓, ROS↑, TumCD↑, AMPK↑, Hif1a↓, GLUT1↓, GLUT3↓, HK2↓, PFK↓, PKM2↓, LDH↓, cMyc↓, BAX↓, cycD1/CCND1↓, PDH↓, ROS↑, Apoptosis↑, eff↑, ACLY↓, FASN↓, Bcl-2↓, Glycolysis↓,
5959- CEL,    Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-κB as a possible target
- in-vitro, Cerv, HeLa
Apoptosis↑, Casp8↑, Casp9↑, cl‑BID↑, MMP↓, NF-kB↑, Dose⇅, chemoPv⇅, COX2/PTGS2↓,
7165- CHA,    The anticancer agent chaetocin is a competitive substrate and inhibitor of thioredoxin reductase
- in-vitro, Cerv, HeLa
ROS↑, TumCD↑, TrxR1↓, other↝, GSR↓, Trx↓, eff↓,
4479- Chit,    Chitosan nanoparticles triggered the induction of ROS-mediated cytoprotective autophagy in cancer cells
- in-vitro, Cerv, HeLa - in-vitro, HCC, SMMC-7721 cell
TumAuto↑, ROS↑, eff↓,
6069- CHL,  PDT,    Anti-Cancer Effect of Chlorophyllin-Assisted Photodynamic Therapy to Induce Apoptosis through Oxidative Stress on Human Cervical Cancer
- in-vitro, Cerv, HeLa
eff↑, ROS↑, Casp8↓, Casp9↑, BAX↑, Cyt‑c↑, Bcl-2↓, AKT1↓,
1145- CHr,    Chrysin inhibits propagation of HeLa cells by attenuating cell survival and inducing apoptotic pathways
- in-vitro, Cerv, HeLa
tumCV↓, BAX↑, BID↑, BOK↑, APAF1↑, TNF-α↑, FasL↑, Fas↑, FADD↑, Casp3↑, Casp7↑, Casp8↑, Casp9↑, Mcl-1↓, NAIP↓, Bcl-2↓, CDK4↓, CycB/CCNB1↓, cycD1/CCND1↓, cycE1↓, TRAIL↑, p‑Akt↓, Akt↓, mTOR↓, PDK1 / PDPK1↓, BAD↓, GSK‐3β↑, AMPK↑, p27/CDKN1B↑, P53↑,
6292- Cro,    Crocetin induces cytotoxicity and enhances vincristine-induced cancer cell death via p53-dependent and -independent mechanisms
- in-vitro, Cerv, HeLa - in-vitro, Lung, A549 - in-vitro, Ovarian, SKOV3
TumCP↓, TumCCA↑, P21↑, Apoptosis↑, eff↑,
945- Cro,    Characterization of the Saffron Derivative Crocetin as an Inhibitor of Human Lactate Dehydrogenase 5 in the Antiglycolytic Approach against Cancer
- in-vitro, Lung, A549 - in-vitro, Cerv, HeLa
LDH↓,
1609- CUR,  EA,    Curcumin and Ellagic acid synergistically induce ROS generation, DNA damage, p53 accumulation and apoptosis in HeLa cervical carcinoma cells
- in-vitro, Cerv, NA
eff↑, Dose∅, ROS↑, DNAdam↑, P53↑, P21↑, BAX↑, Dose∅,
1980- CUR,  Rad,    Thioredoxin reductase-1 (TxnRd1) mediates curcumin-induced radiosensitization of squamous carcinoma cells
- in-vitro, Cerv, HeLa - in-vitro, Laryn, FaDu
selectivity↑, RadioS↑, TrxR↓, ROS↑, ERK↑, Dose∅, cl‑PARP↑,
1978- CUR,    Curcumin targeting the thioredoxin system elevates oxidative stress in HeLa cells
- in-vitro, Cerv, HeLa
TrxR1↓, ROS↑, DNA-PK↑, eff↑, Trx↓, Trx1↓,
1977- CUR,    Synthesis and evaluation of curcumin analogues as potential thioredoxin reductase inhibitors
- in-vitro, BC, MCF7 - in-vitro, Cerv, HeLa - in-vitro, Lung, A549
TrxR↓, Dose↝, eff↑,
6229- CUR,    Curcumin inhibits NF-kB and Wnt/β-catenin pathways in cervical cancer cells
- in-vitro, Cerv, NA
TumCI↓, TumCP↓, NF-kB↓, Wnt↓, β-catenin/ZEB1↓,
6226- CUR,  Rad,    Analysis of Curcumin as a Radiosensitizer in Cancer Therapy with Serum Survivin Examination: Randomised Control Trial
- Trial, Cerv, NA
survivin↓, RadioS↑, toxicity↓,
477- CUR,    Curcumin induces G2/M arrest and triggers autophagy, ROS generation and cell senescence in cervical cancer cells
- in-vitro, Cerv, SiHa
TumCP↓, TumCCA↑, Apoptosis↑, TumAuto↑, CycB/CCNB1↓, CDC25↓, ROS↑, p62↑, LC3‑Ⅱ/LC3‑Ⅰ↑, cl‑Casp3↑, cl‑PARP↑, P53↑, P21↑,

Showing Research Papers: 1 to 50 of 178
Page 1 of 4 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 178

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

CR↑, 1,   OGFr↑, 2,   UBE2L3/UBCH7↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↓, 1,   Catalase∅, 1,   compI↓, 1,   ENOX2↓, 3,   Ferroptosis↑, 5,   GPx↓, 1,   GPx↑, 1,   GPx1∅, 1,   GPx4↓, 3,   GSH↓, 12,   GSH↑, 1,   GSH/GSSG↓, 1,   GSR↓, 1,   H2O2↑, 2,   HO-1↓, 2,   HO-1↝, 1,   Iron↑, 2,   i-Iron↑, 1,   Keap1↝, 1,   lipid-P↑, 9,   MDA↑, 1,   i-MDA↑, 1,   NADH↓, 1,   NADH↑, 1,   NADHdeh?, 1,   NRF2↓, 2,   NRF2↑, 1,   OXPHOS↓, 1,   ROS↓, 2,   ROS↑, 73,   i-ROS↑, 1,   mt-ROS↑, 2,   SOD↓, 3,   SOD↑, 1,   SOD∅, 1,   Thiols↓, 1,   Trx↓, 3,   Trx1↓, 1,   TrxR↓, 8,   TrxR1↓, 3,   TrxR2↓, 1,   VDAC1↓, 1,   xCT/SLC7A11↓, 3,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 1,   ATP↓, 4,   ATP⇅, 1,   BOK↑, 1,   CDC25↓, 1,   compIII↓, 1,   ETC↓, 1,   p‑MEK↓, 1,   MMP↓, 25,   MMP∅, 1,   mtDam↑, 3,   OCR↓, 1,   Raf↓, 1,   p‑Raf↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACC↓, 1,   ACLY↓, 1,   ACSL4↑, 1,   ACSL4↝, 1,   AKT1↓, 1,   AMPK↑, 7,   CAIX/CA9↓, 1,   cMyc↓, 2,   cMyc↑, 1,   ECAR↓, 1,   FASN↓, 2,   GLS↓, 1,   GlucoseCon↓, 3,   Glycolysis↓, 6,   HK2↓, 2,   IDO1↓, 1,   lactateProd↓, 4,   LDH↓, 4,   LDH↑, 1,   LDH↝, 1,   LDH∅, 1,   LDHA↓, 1,   NADPH↓, 1,   NPC1L1↓, 1,   PDH↓, 1,   PDK1 / PDPK1↓, 3,   PFK↓, 1,   PIK3CA↑, 1,   PKM2↓, 7,   RARβ↑, 1,   p‑S6K↓, 1,   SIRT1↓, 1,   SREBP1/SREBF1↓, 2,   Warburg↓, 1,  

Cell Death(tgid=5) ⓘ

AhR↑, 2,   Akt↓, 9,   Akt↑, 1,   p‑Akt↓, 8,   APAF1↑, 2,   Apoptosis↓, 2,   Apoptosis↑, 55,   mt-Apoptosis↑, 1,   aSmase↑, 1,   BAD↓, 1,   BAD↑, 1,   Bak↑, 1,   BAX↓, 1,   BAX↑, 14,   Bax:Bcl2↑, 2,   Bcl-2↓, 12,   Bcl-xL↓, 1,   Bcl-xL↑, 1,   BID↑, 2,   cl‑BID↑, 1,   Casp↑, 5,   Casp12↑, 1,   Casp12↝, 1,   Casp3↑, 26,   cl‑Casp3↓, 1,   cl‑Casp3↑, 3,   proCasp3↓, 1,   Casp6↑, 1,   Casp7↑, 3,   Casp8↓, 1,   Casp8↑, 8,   proCasp8↓, 1,   Casp9↑, 19,   cl‑Casp9↓, 1,   cl‑Casp9↑, 1,   proCasp9↓, 1,   CK2↓, 1,   Cyt‑c↓, 1,   Cyt‑c↑, 11,   DR4↑, 2,   DR5↑, 2,   FADD↑, 2,   Fas↑, 2,   FasL↑, 2,   Ferroptosis↑, 5,   hTERT/TERT↓, 4,   JNK↑, 1,   p‑JNK↑, 1,   MAPK↓, 1,   Mcl-1↓, 1,   MDM2↓, 1,   Myc↓, 1,   NAIP↓, 1,   Necroptosis↑, 1,   necrosis↑, 2,   p27/CDKN1B↑, 4,   p38↑, 2,   p‑p38↑, 1,   Paraptosis↑, 1,   Proteasome↓, 1,   SK↓, 1,   survivin↓, 2,   Telomerase↓, 2,   TRAIL↑, 2,   TRAIL⇅, 1,   TRAILR↑, 1,   TumCD↑, 14,  

Kinase & Signal Transduction(tgid=6) ⓘ

HER2/EBBR2↓, 2,   Sp1/3/4↓, 3,   Sp1/3/4↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

ChrMod↝, 2,   cJun↑, 1,   EZH2↓, 4,   ac‑H3↓, 1,   ac‑H4↓, 1,   HATs↓, 1,   HATs↑, 1,   other↝, 6,   other∅, 1,   tumCV↓, 23,   tumCV∅, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

c-ATF6↑, 1,   CHOP/DDIT3↑, 4,   eIF2α↓, 1,   p‑eIF2α↑, 1,   ER Stress↓, 3,   ER Stress↑, 11,   ERStress↑, 1,   GRP78/BiP↓, 2,   GRP78/BiP↑, 4,   GRP94↑, 3,   HSP70/HSPA5↑, 3,   HSP70/HSPA5∅, 1,   HSP90↓, 1,   HSPs↑, 1,   IRE1↑, 1,   p‑PERK↓, 1,   p‑PERK↑, 1,   UPR↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

APA↑, 1,   ATG3↑, 1,   ATG5↓, 1,   ATG5↑, 1,   Beclin-1/ATG6↓, 2,   Beclin-1/ATG6↑, 1,   Beclin-1/ATG6⇅, 1,   LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   LC3II↓, 1,   LC3II↑, 2,   p62↓, 1,   p62↑, 2,   TFEB↑, 1,   TumAuto↓, 1,   TumAuto↑, 11,   mt-TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

BRCA2↓, 1,   DNA-PK↑, 2,   DNAdam↑, 15,   DNMT1↓, 3,   DNMT3A↓, 3,   DNMTs↓, 5,   G9a↓, 1,   P53↑, 13,   PARP↑, 1,   cl‑PARP↓, 1,   cl‑PARP↑, 12,   PARP1↑, 1,   RAD51↓, 1,   TP53↑, 1,   UHRF1↓, 1,   γH2AX↑, 2,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 1,   CDK2↓, 1,   CDK4↓, 2,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 3,   cycD1/CCND1↓, 5,   cycE/CCNE↓, 1,   cycE1↓, 1,   mitA↑, 1,   P21↑, 13,   TumCCA↓, 1,   TumCCA↑, 24,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 2,   CD133↓, 1,   CD24↓, 2,   CD44↓, 2,   p‑cDC2↓, 1,   CEBPA↑, 1,   CSCs↓, 9,   CTNNB1↓, 1,   EMT↓, 3,   EMT↝, 1,   ERK↓, 1,   ERK↑, 1,   p‑ERK↓, 2,   GSK‐3β↓, 1,   GSK‐3β↑, 1,   p‑GSK‐3β↓, 1,   HDAC↓, 4,   HDAC1↓, 3,   HDAC11↓, 1,   HDAC2↓, 2,   HDAC3↓, 1,   HDAC4↓, 1,   HDAC6↓, 1,   HDAC8↓, 1,   HMTs↓, 1,   HMTs↑, 1,   IGF-1↓, 1,   IGFBP7↑, 1,   MAP2K1/MEK1↓, 1,   mTOR↓, 14,   mTOR⇅, 1,   p‑mTOR↓, 1,   Nanog↓, 1,   NOTCH↓, 1,   NOTCH1↓, 1,   OCT4↓, 1,   P70S6K↓, 1,   PI3K↓, 9,   p‑PI3K↓, 3,   Pirin↓, 1,   PTEN↑, 4,   RAS?, 1,   RAS↓, 1,   SOX2↓, 1,   STAT3↓, 5,   p‑STAT3↓, 1,   TOP1↓, 1,   TOP2↓, 2,   TumCG↓, 16,   TumCG↑, 1,   Wnt↓, 4,  

Migration(tgid=13) ⓘ

ATPase↑, 1,   Ca+2↓, 1,   Ca+2↑, 3,   CD31/PECAM-1↓, 1,   CDH1↑, 1,   CEA↓, 1,   E-cadherin↑, 3,   Ki-67↓, 1,   LAMP1?, 1,   MMP-10↓, 1,   MMP2↓, 3,   MMP7↓, 1,   MMP9↓, 5,   N-cadherin↓, 1,   PIR↓, 1,   Slug↓, 2,   SMAD3↓, 1,   p‑SMAD4↓, 1,   Snail↓, 1,   T-cadherin↑, 2,   TET1↑, 1,   TGF-β↑, 1,   TIMP1↑, 1,   TIMP3↑, 1,   TSC1↑, 1,   TumCA↓, 1,   TumCI↓, 13,   TumCMig↓, 20,   TumCP↓, 38,   TumCP↑, 1,   TumMeta↓, 2,   Twist↓, 1,   uPA↓, 1,   Vim↓, 2,   Vim↑, 1,   vinculin↓, 1,   Zeb1↓, 1,   ac‑α-tubulin↑, 1,   β-catenin/ZEB1↓, 5,   β-catenin/ZEB1↑, 1,   p‑β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 4,   EGFR↓, 1,   EPR↑, 1,   Hif1a↓, 3,   Hypoxia↓, 1,   NO↓, 1,   TAMS↓, 1,   VEGF↓, 2,  

Barriers & Transport(tgid=15) ⓘ

CellMemb↑, 1,   GLUT1↓, 2,   GLUT3↓, 1,   P-gp/ABCB1↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 4,   CXCR4↓, 1,   IL10↓, 1,   IL18↓, 1,   IL1β↓, 2,   IL2↓, 1,   IL6↓, 1,   IL6↑, 1,   IL8↓, 1,   Imm↑, 3,   Inflam↓, 2,   JAK↓, 1,   M2 MC↓, 1,   NF-kB↓, 7,   NF-kB↑, 1,   p65↓, 1,   PD-1↓, 1,   PD-L1↓, 2,   SOCS1↑, 1,   T-Cell↑, 1,   TNF-α↑, 2,  

Cellular Microenvironment(tgid=17) ⓘ

ADAM17↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 3,   BioAv↑, 3,   ChemoSen↑, 11,   ChemoSen⇅, 1,   Dose?, 1,   Dose↑, 2,   Dose⇅, 1,   Dose↝, 17,   Dose∅, 5,   eff↓, 18,   eff↑, 35,   eff↝, 4,   Half-Life↑, 1,   RadioS↑, 10,   selectivity↓, 2,   selectivity↑, 24,   TET2↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

BloodF↑, 1,   CEA↓, 1,   E6↓, 3,   E7↓, 2,   EGFR↓, 1,   EZH2↓, 4,   HER2/EBBR2↓, 2,   hTERT/TERT↓, 4,   IL6↓, 1,   IL6↑, 1,   Ki-67↓, 1,   LDH↓, 4,   LDH↑, 1,   LDH↝, 1,   LDH∅, 1,   Myc↓, 1,   PD-L1↓, 2,   TP53↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 8,   AntiTum↑, 3,   chemoP↑, 2,   chemoPv↑, 1,   chemoPv⇅, 1,   OS↑, 1,   PARP16↓, 1,   QoL↑, 1,   Risk↓, 2,   toxicity↓, 3,   TumVol↓, 1,   TumVol⇅, 1,   TumW⇅, 1,  
Total Targets: 411

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiBio↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 8,   HO-1↑, 1,   NRF2↑, 1,   ROS↓, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

LDH↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 4,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 3,   BioEnh↑, 1,   Half-Life∅, 1,  

Clinical Biomarkers(tgid=22) ⓘ

GutMicro↑, 1,   LDH↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   AntiDiabetic↑, 3,   AntiTum↑, 1,   cardioP↑, 1,   hepatoP↑, 1,   neuroP↑, 2,   toxicity↓, 1,   toxicity↑, 1,   toxicity↝, 1,   toxicity∅, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiViral↑, 1,   Bacteria↓, 2,  
Total Targets: 26

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:29  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page